Table 4. Maximum enhancement (ME) in HU of the craniocervical vessels in body weight-tailored groups and controls.
| Multiple comparison (p-value) | Multiple comparison (p-value) | Paired comparison (p-value) | ||||||||||||
| Vascular territory | Group 1 (1.5 ml/kg) | Group 2 (1.0 ml/kg) | Group 3 (0.5 ml/kg) | Groups | Control 1 | Control 2 | Control 3 | Controls | Group 1/Group 2 | Group 1/Group 3 | Group 2/Group 3 | Group1/Control 1 | Group 2/Control 2 | Group 3/Control 3 |
| CCA | 371 (340–473) | 435 (353–464) | 354 (259–385) | .001** | 345 (284–452) | 363 (312–434) | 376 (321–440) | .550 | .783 | .003** | .001** | .027* | .027* | .013* |
| ECA | 364 (321–480) | 422 (353–459) | 318 (257–360) | <.001** | 338 (265–419) | 360 (315–413) | 387 (324–427) | .118 | .576 | .001** | <.001** | .038* | .033* | .001** |
| ICAex | 394 (341–498) | 414 (330–495) | 291 (190–343) | <.001** | 331 (277–424) | 367 (311–419) | 380 (331–450) | .082 | .791 | <.001** | <.001** | .004** | .026* | <.001** |
| ICAin | 411 (351–501) | 453 (315–489) | 256 (178–326) | <.001** | 347 (288–439) | 383 (321–431) | 400 (318–433) | .358 | .668 | <.001** | <.001** | .010* | .102 | <.001** |
| ACA | 334 (269–370) | 317 (230–371) | 172(124-229) | <.001** | 252 (169–302) | 267 (200–305) | 287 (239–322) | .084 | .444 | <.001** | <.001** | <.001** | .020* | <.001** |
| MCA | 359 (307–436) | 377 (296–465) | 215 (149–289) | <.001** | 305 (254–372) | 340 (270–375) | 360 (301–400) | .069 | .620 | <.001** | <.001** | .003** | .034* | <.001** |
| PcomA | 251 (165–324) | 248 (220–306) | 125 (75–168) | <.001** | 154 (96–243) | 215 (124–275) | 161 (92–216) | .343 | .682 | <.001** | <.001** | .012* | .054 | .009** |
| PCA | 292 (255–362) | 312 (249–367) | 206 (122–245) | <.001** | 280 (222–312) | 287 (238–337) | 295 (248–349) | .212 | .953 | <.001** | <.001** | .012* | .234 | <.001** |
| SCA | 188 (157–246) | 191 (143–216) | 116 (88–173) | <.001** | 155 (126–173) | 159 (141–230) | 160 (133–215) | .171 | .397 | <.001** | <.001** | <.001** | .538 | <.001** |
| AICA | 157 (135–194) | 166 (135–198) | 120 (102–123) | <.001** | 139 (115–188) | 147 (124–178) | 121 (114–143) | .053 | .719 | <.001** | <.001** | .159 | .208 | .108 |
| VA | 363 (291–421) | 395 (313–440) | 285 (210–311) | <.001** | 328 (255–373) | 336 (290–393) | 338 (282–389) | .716 | .491 | <.001** | <.001** | .057 | .024* | <.001** |
| PICA | 199 (144–259) | 186 (158–222) | 153 (107–173) | <.001** | 172 (123–248) | 145 (110–202) | 182 (129–228) | .261 | .430 | .001** | .001** | .119 | .012* | .061 |
| AcomA | 245 (197–315) | 230 (160–309) | 199 (138–223) | .011* | 272 (159–294) | 223 (154–284) | 243 (192–292) | .712 | .633 | .003** | .028* | .391 | .445 | .022* |
| BA | 358 (316–402) | 365 (304–412) | 265 (171–336) | .001** | 311 (252–367) | 341 (262–382) | 334 (307–392) | .405 | .914 | .001** | .001** | .056 | .273 | .002** |
ME data are presented as medians (25th percentile–75th percentile). Overall p-value was calculated by Kruskal-Wallis test. Pairwise comparison was performed by means of Mann-Whitney U-test with interim analyses by Bonferroni-Holm adjustment. *A p-value<0.05 was considered statistically significant. ** p<0.01.